The Effect of Trimebutine on the Overlap Syndrome Model of Guinea Pigs
- Author:
Zahid HUSSAIN
1
;
Da Hyun JUNG
;
Young Ju LEE
;
Hyojin PARK
Author Information
- Publication Type:Original Article
- Keywords: Corticotropin-releasing factor; Guinea pigs; Overlap syndrome; Trimebutine
- MeSH: Animals; Charcoal; Colon; Corticotropin-Releasing Hormone; Dyspepsia; Guinea Pigs; Guinea; Humans; Irritable Bowel Syndrome; Male; Peptides; Trimebutine
- From:Journal of Neurogastroenterology and Motility 2018;24(4):669-675
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common gastrointestinal (GI) disorders and these patients frequently overlap. Trimebutine has been known to be effective in controlling FD co-existing diarrhea-dominant IBS, however its effect on overlap syndrome (OS) patients has not been reported. Therefore, we investigated the effect of trimebutine on the model of OS in guinea pigs. METHODS: Male guinea pigs were used to evaluate the effects of trimebutine in corticotropin-releasing factor (CRF) induced OS model. Different doses (3, 10, and 30 mg/kg) of trimebutine were administered orally and incubated for 1 hour. The next treatment of 10 μg/kg of CRF was intraperitoneally injected and stabilized for 30 minutes. Subsequently, intragastric 3 mL charcoal mix was administered, incubated for 10 minutes and the upper GI transit analyzed. Colonic transits were assessed after the same order and concentrations of trimebutine and CRF treatment by fecal pellet output assay. RESULTS: Different concentrations (1, 3, and 10 μg/kg) of rat/human CRF peptides was tested to establish the OS model in guinea pigs. CRF 10 μg/kg was the most effective dose in the experimental OS model of guinea pigs. Trimebutine (3, 10, and 30 mg/kg) treatment significantly reversed the upper and lower GI transit of CRF induced OS model. Trimebutine significantly increased upper GI transit while it reduced fecal pellet output in the CRF induced OS model. CONCLUSIONS: Trimebutine has been demonstrated to be effective on both upper and lower GI motor function in peripheral CRF induced OS model. Therefore, trimebutine might be an effective drug for the treatment of OS between FD and IBS patients.
